Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP-001 thorough QT study in healthy volunteers
NCT06649942Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of KP001 (4 arms), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoint: Largest time-matched placebo-corrected change from baseline in QTcF at 24 hours. Started Oct 2024; status: completed.
02
Drugs
KP001
Beyond the preview
Go deeper on NCT06649942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649942.